Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 14/20 | 0.57 |
| ▸ | SELP | P16109 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613575 | 0.94 | SELE (0.57) | SELESELP | |
| SCHEMBL9613582 | 0.92 | SELE (0.52) | SELESELP | |
| SCHEMBL12942205 | 0.90 | SELE (0.56) | SELESELP | |
| SCHEMBL13824366 | 0.89 | SELE (0.49) | SELESELP | |
| SCHEMBL9613574 | 0.84 | SELE (0.43) | SELESELP | |
| SCHEMBL9613569 | 0.83 | SELE (0.55) | SELESELP | |
| SCHEMBL9613558 | 0.83 | SELE (0.75) | SELESELP | |
| SCHEMBL12945076 | 0.82 | SELE (0.51) | SELESELP | |
| SCHEMBL12902991 | 0.82 | SELE (0.56) | SELESELP | |
| SCHEMBL12257313 | 0.81 | SELE (0.72) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| WO-2008100453-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | SELE 2/4885SELP 1/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | SELE 2/4885SELP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.